SEC Form 4 · accession 0001140361-18-027202
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Pendarvis
Officer — Chief Administrative Officer
Period of report
Jun 1, 2018
Accepted (ET)
Jun 4, 2018 · 5:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common StockF1,F2 | Jun 1, 2018 | F | 167 | $103.56 | D | 99,083 | D | |
| ResMed Common Stock | Jun 4, 2018 | M | 2,810 | $38.98 | A | 101,893 | D | |
| ResMed Common Stock | Jun 4, 2018 | S | 2,810 | $103.75 | D | 99,083 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock OptionsF4 | $38.98 | Jun 4, 2018 | M | 2,810 | D | Nov 11, 2013 | Nov 15, 2019 | ResMed Common Stock | 2,810 | 14,050 | D |
Explanation of responses
- F1Disposition to issuer for tax withholding on vesting of performance-based restricted stock units granted on 06/01/2017.
- F2Includes 145 shares of ResMed stock purchased on April 30, 2018, through the ResMed Employee Stock Purchase Plan.
- F3The transaction was conducted under a Rule 10b5-1 plan.
- F4Represents date options first became exercisable. Options vest 1/3 per year.